- $849.87m
- $760.36m
- $14.08m
Second judge says US not liable in Moderna COVID-19 vaccine patent case (updated)
Second judge says US not liable in Moderna COVID-19 vaccine patent case
What to Watch in the Day Ahead - Wednesday, April 26
U.S. STOCKS ON THE MOVE-Alphabet, First Republic Bank, Microsoft
Arbutus Biopharma falls on FDA clinical hold for immune drug trial
Brief: Arbutus Biopharma Says FDA Indicated They Will Provide An Official Clinical Hold Letter To Arbutus Within 30 Days
Brief: Arbutus To Report First Quarter 2023 Financial Results And Provide Corporate Update
Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight (updated)
Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight
Arbutus files patent infringement lawsuit against Pfizer/BioNTech (updated)
Arbutus files patent infringement lawsuit against Pfizer/BioNTech
Brief: Arbutus Doses First Subject In Phase 1 Clinical Trial With Its Oral RNA Destabilizer
Moderna loses bid to shift liability in COVID-19 vaccine patent case
Arbutus Biopharma Corp reports results for the quarter ended in December - Earnings Summary
Brief: Arbutus Reports Fourth Quarter And Year End 2022 Financial Results And Corporate Update
Arbutus Biopharma Corp expected to post a loss of 13 cents a share - Earnings Preview
Brief: Arbutus To Report Fourth Quarter And Year End 2022 Financial Results And Provide Corporate Update
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
Roivant Sciences rises after pricing upsized stock offering